EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prognostic value of programmed death ligand‐1 and programmed death‐1 expression in patients with upper tract urothelial carcinoma

Luca Campedel, Eva Compérat, Géraldine Cancel-Tassin iD, Justine Varinot, Christian Pfister, Clara Delcourt, Françoise Gobet, Mathieu Roumiguié iD, Pierre-Marie Patard, Gwendoline Daniel, Pierre Bigot, Julie Carrouget iD und 23 weitere

BJU International · 2023

DOI: 10.1111/bju.16129 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, 2023. Verfasst von Luca Campedel und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France. Hauptthemen laut MEDLINE: B7-H1 Antigen, Programmed Cell Death 1 Receptor, Carcinoma, Transitional Cell, Ureteral Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Institut National Du Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the prognostic value of programmed death ligand‐1 (PD‐L1) and programmed death‐1 (PD‐1) expression in patients with upper tract urothelial carcinoma (UTUC). Patients and methods A retrospective multicentre study was conducted in 283 patients with UTUC treated with radical nephroureterectomy (RNU) between 2000 and 2015 at 10 French hospitals. Immunohistochemistry analyses were performed using 2 mm‐core tissue microarrays with NAT105® and 28.8® antibodies at a 5% cut‐off for positivity on tumour cells and tumour‐infiltrating lymphocytes to evaluate PD‐L1 and PD‐1 expression, respectively. Multivariable Cox regression models were used to determine the independent predictors of recurrence‐free (RFS), cancer‐specific (CSS) and overall survival (OS).

Results

Overall, 63 (22.3%) and 220 (77.7%) patients with UTUC had PD‐L1‐positive and ‐negative disease, respectively, while 91 (32.2%) and 192 (67.8%) had PD‐1‐positive and ‐negative disease, respectively. Patients who expressed PD‐L1 or PD‐1 were more likely to have pathological tumour stage ≥pT2 (68.3% vs 49.5%, P = 0.009; and 69.2% vs 46.4%, P < 0.001, respectively) and high‐grade (90.5% vs 70.0%, P = 0.001; and 91.2% vs 66.7%, P < 0.001, respectively) disease with lymphovascular invasion (52.4% vs 17.3%, P < 0.001; and 39.6% vs 18.2%, P < 0.001, respectively) as compared to those who did not. In multivariable Cox regression analysis adjusting for each other, PD‐L1 and PD‐1 expression were significantly associated with decreased RFS (hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.09–3.08, P = 0.023; and HR 1.59, 95% CI 1.01–2.54, P = 0.049; respectively), CSS (HR 2.73, 95% CI 1.48–5.04, P = 0.001; and HR 1.96, 95% CI 1.12–3.45, P = 0.019; respectively) and OS (HR 2.08, 95% CI 1.23–3.53, P = 0.006; and HR 1.71, 95% CI 1.05–2.78, P = 0.031; respectively). In addition, multivariable Cox regression analyses evaluating the four‐tier combination of PD‐L1 and PD‐1 expression showed that only PD‐L1/PD‐1‐positive patients ( n = 38 [13.4%]) had significantly decreased RFS (HR 3.07, 95% CI 1.70–5.52; P < 0.001), CSS (HR 5.23, 95% CI 2.62–10.43; P < 0.001) and OS (HR 3.82, 95% CI 2.13–6.85; P < 0.001) as compared to those with PD‐L1/PD‐1‐negative disease ( n = 167 [59.0%]).

Conclusions

We observed that PD‐L1 and PD‐1 expression were both associated with adverse pathological features that translated into an independent and cumulative adverse prognostic value in UTUC patients treated with RNU.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenProgrammed Cell Death 1 ReceptorCarcinoma, Transitional CellUreteral NeoplasmsKidney NeoplasmsUrologic NeoplasmsHumansMaleFemaleAgedRetrospective StudiesPrognosisMiddle AgedAged, 80 and overNephroureterectomyBiomarkers, Tumor

Stichwörter der Autor:innen

PD-1PD-L1prognosticradical nephroureterectomyupper tract urothelial carcinoma

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Oncology, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
  • GRC n°5, Predictive Onco-Urology, Sorbonne Université, Paris, France.
  • Departement of Pathology, Tenon Hospital, AP-HP, Paris, France.
  • CeRePP, Tenon Hospital, Paris, France.
  • Department of Urology, Rouen Hospital, Rouen, France.
  • Department of Pathology, Rouen Hospital, Rouen, France.

ORCID-Profile: Géraldine Cancel-Tassin, Mathieu Roumiguié, Julie Carrouget, Priscilla Léon, Cédric Lebacle, Xavier Matillon

Förderung

  • Institut National Du Cancer

Zitieren

APA

Campedel, L., Compérat, E., Cancel-Tassin, G., Varinot, J., Pfister, C., Delcourt, C., Gobet, F., Roumiguié, M., Patard, P. M., Daniel, G., Bigot, P., Carrouget, J., Eymerit, C., Larré, S., Léon, P., Durlach, A., Ruffion, A., de Mazancourt, E. S., Decaussin-Petrucci, M., …, & Seisen, T. (2023). Prognostic value of programmed death ligand‐1 and programmed death‐1 expression in patients with upper tract urothelial carcinoma. BJU International. https://doi.org/10.1111/bju.16129

Vancouver

Campedel L, Compérat E, Cancel-Tassin G, Varinot J, Pfister C, Delcourt C, et al. Prognostic value of programmed death ligand‐1 and programmed death‐1 expression in patients with upper tract urothelial carcinoma. BJU International. 2023. doi:10.1111/bju.16129

BibTeX
@article{Campedel2023,
  author = {Campedel, Luca and Compérat, Eva and Cancel-Tassin, Géraldine and Varinot, Justine and Pfister, Christian and Delcourt, Clara and Gobet, Françoise and Roumiguié, Mathieu and Patard, Pierre-Marie and Daniel, Gwendoline and Bigot, Pierre and Carrouget, Julie and Eymerit, Caroline and Larré, Stéphane and Léon, Priscilla and Durlach, Anne and Ruffion, Alain and de Mazancourt, Emilien Seizilles and Decaussin-Petrucci, Myriam and Bessède, Thomas and Lebacle, Cédric and Ferlicot, Sophie and Robert, Grégoire and Vuong, Nam-Son and Philip, Magali and Crouzet, Sébastien and Matillon, Xavier and Mège-Lechevallier, Florence and Lang, Hervé and Mouracade, Pascal and Lindner, Véronique and Gougis, Paul and Cussenot, Olivier and Rouprêt, Morgan and Seisen, Thomas},
  title = {Prognostic value of programmed death ligand‐1 and programmed death‐1 expression in patients with upper tract urothelial carcinoma},
  journal = {BJU International},
  year = {2023},
  doi = {10.1111/bju.16129}
}
Kostenlos starten →